Molecular Partners

Contributing Author

Recent Articles by Molecular Partners

11 hours	Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting MOLN GlobeNewswire
Nov-12	Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action MOLN GlobeNewswire
Nov-03	Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 MOLN GlobeNewswire
Nov-03	Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting MOLN GlobeNewswire
Oct-30	Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 MOLN GlobeNewswire
Aug-25	Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 MOLN GlobeNewswire
Aug-21	Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics MOLN GlobeNewswire
Jun-22	Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 MOLN GlobeNewswire
Jun-11	Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 MOLN GlobeNewswire
Jun-10	Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway MOLN GlobeNewswire
May-19	Molecular Partners to Present at Upcoming Investor Conferences MOLN GlobeNewswire
May-15	Molecular Partners Reports Financial Results and Highlights from Q1 2025 MOLN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.